Free T3 Test: Normal Range, T3 Toxicosis and What Lowers T3
Research information only. Not medical advice. 18+ only. Not FDA-approved for human therapeutic use.

Free T3 blood test

Free triiodothyronine (free T3). Also called: FT3, Free triiodothyronine, Triiodothyronine, free, T3, free

Biomarker guideLast updated: November 3, 2026

Free T3 is the unbound form of the active thyroid hormone. Labcorp prints 2.0-4.4 pg/mL and Quest 2.3-4.2 pg/mL for adults. It is mainly used when TSH is low, to find hyperthyroidism that shows only in T3.

LOINC 3051-0Hormones

Not part of a standard Thyroid Panel. Free T3 is ordered on its own, usually after a low TSH.

At a glance

What it measuresThe unbound triiodothyronine (T3) in blood, the active thyroid hormone, most of which is made from T4 outside the thyroid.
SampleSerum (preferred) or plasma. Stop high-dose biotin at least 72 hours before.
Adult rangesLabcorp 2.0-4.4 pg/mL (over 19 years); Quest 2.3-4.2 pg/mL (over 20 years).
Peptides that move itRaised by Thyrotropin-Releasing Hormone (TRH), MK-677 (Ibutamoren) and, where leptin is deficient, Leptin; lowered by Octreotide and Lanreotide in TSH-secreting pituitary tumors.
Lab codeLOINC 3051-0 (Labcorp 010389, Quest 34429); 29239-1 by dialysis (Quest 36598)

What is Free T3?

T3 is the thyroid hormone that acts on cells. It makes up only about 5% of the thyroid hormone in blood, and only 0.25% of it is free; most T3 is made from T4 in tissues outside the thyroid. Free T3 is mainly ordered after a low TSH, to diagnose and follow hyperthyroidism, especially when free T4 is not raised.

Sources: [1] [2] [3]

How it is made and regulated

Where it is made

The thyroid releases some T3 directly, but most is made from T4 in tissues outside the thyroid: people without a thyroid still make T3 from the T4 they take.

Sources: [3] [1]

What controls it

TSH drives the thyroid, and free T4 and T3 feed back to lower it. Conversion of T4 to T3 is also regulated in the tissues: growth hormone speeds it up, through the deiodinase enzyme.

Sources: [4] [5] [6]

How it travels in the blood

Almost all T3 is bound to carrier proteins; Labcorp notes that free T3 is unaffected by changes in those proteins, which is why it is used to clarify thyroid status when a binding-protein problem is suspected.

Sources: [1] [2]

How long it lasts

Free T3 responds to energy intake: it falls with diet-induced weight loss, with or without leptin, and fell markedly in people with diabetes after weight-loss treatment (bariatric surgery, a GLP-1 drug or lifestyle change, analysed together).

Sources: [7] [8]

What it does

Because the body keeps T3 steady by converting more T4, free T3 may not drop until well after TSH and free T4 have changed in an underactive thyroid. In an overactive one, T3 can rise on its own (T3 toxicosis).

Sources: [2]

Reference ranges

Adult ranges are similar at the two labs; children run higher. Quest's dialysis test is the only one with a pregnancy range, and it reports in pg/dL.

Labcorp (test 010389)

Method: Electrochemiluminescence immunoassay (ECLIA), Roche cobas. Labcorp test page (retrieved November 3, 2026).

GroupRange (pg/mL)
Over 19 years2.0-4.4
Children and teens
GroupRange (pg/mL)
0 to 3 days2.0-7.9
4 to 30 days2.0-5.2
31 days to 12 months1.6-6.4
13 months to 5 years2.0-6.0
6 to 10 years2.7-5.2
11 to 19 years2.3-5.0

As printed on Labcorp's test page for 010389. No pregnancy range is printed.

Quest Diagnostics (test 34429)

Method: Immunoassay. Quest Diagnostics test page (retrieved November 3, 2026).

GroupRange (pg/mL)
Over 20 years2.3-4.2
Children and teens
GroupRange (pg/mL)
1-23 months3.3-5.2
2-12 years3.3-4.8
13-20 years3.0-4.7

From Quest's test directory. Quest gives no range for babies under 1 month.

Free T3 immunoassays differ between labs; compare results from the same lab. Antibodies to thyroid hormones can interfere with free hormone immunoassays. Quest's tracer-dialysis test (36598) reports in pg/dL: 210-440 pg/dL for adults and 200-380 pg/dL in pregnancy.

Units: Labs outside the US report free T3 in pmol/L. Divide pmol/L by 1.536 to get pg/mL. [10]

Sources: [1] [2] [9]

Is there an "optimal" range?

Free T3 has no agreed "optimal" level, and guidelines do not use it to manage an underactive thyroid.

The lab interval

Labcorp 2.0-4.4; Quest 2.3-4.2 pg/mL

Labcorp 010389 and Quest 34429

The adult ranges the two labs print.

Sources: [1] [2]

Not a test for an underactive thyroid

Use TSH and free T4 instead

Quest Diagnostics

Free T3 may not drop until well after TSH and free T4 have changed, so it has limited use when hypothyroidism is suspected.

Sources: [2]

TSH guides treatment

TSH target, not a T3 target

American Thyroid Association (2014)

Levothyroxine stays the standard of care, its dose is adjusted by TSH, and the task force found no consistently strong evidence that adding T3 improves outcomes.

Sources: [11]

Sex- and population-specific limits

3.46-6.04 pmol/L in men; 3.46-5.76 in women

Turkish multicenter study (2026)

More than 100,000 results gave slightly different adult free T3 intervals for men and women on one platform, arguing for locally derived ranges.

Sources: [12]

What raises it

FactorHowHow much
Overactive thyroid, including T3 toxicosisConditionGraves disease or a hot nodule can raise free T3 while free T4 stays normal.Up to 10% of people with proven hyperthyroidism [2]
Growth hormone therapyHormoneGrowth hormone speeds conversion of T4 to T3.Median 2.38 to 2.78 pg/mL in adults with growth hormone deficiency [5]
GH secretagogues and TRHPeptideMK-677 (Ibutamoren) raised free T3 after 8 weeks, and repeated Thyrotropin-Releasing Hormone (TRH) raised it modestly.+12.5% on TRH 2 mg/day for 3 weeks [13] [14]
Leptin replacementPeptideWhere leptin is deficient, as in lipodystrophy, Leptin (metreleptin) raises free T3.+19.4% over 14 days in lipodystrophy [15]

What lowers it

FactorHowHow much
Weight loss and calorie restrictionLifestyleFree T3 falls as the body adapts to less energy, whatever the method of weight loss.No published magnitude [7] [8]
Late hypothyroidismConditionFree T3 is held up by extra T4 conversion and may fall only well after TSH and free T4 have changed.No published magnitude [2]
Somatostatin and its analogsPeptideOctreotide and Lanreotide lower high free T3 in TSH-secreting pituitary tumors, and Somatostatin lowered it in an overactive thyroid.14.6 to 8.3 pmol/L on lanreotide over 6 months [16] [17]
ACTH and glucocorticoidsHormoneA single large Adrenocorticotropic Hormone (ACTH) dose briefly lowered total T3.No published magnitude [18]

Peptides that affect Free T3

How each peptide in our library has been shown to change free T3, strongest evidence first. Rows marked total T3 measured total rather than free T3. Growth hormone peptides tend to raise it, somatostatin analogs lower it in TSH-secreting pituitary tumors, and the GLP-1 drugs that have been studied did not change it. Weight loss itself lowers free T3, so a fall on a weight-loss drug may reflect the weight loss. No study has reported free T3 after dosing Semaglutide, Tirzepatide, Retatrutide, Dulaglutide, Lixisenatide, Tesamorelin, CJC-1295, Ipamorelin, Mod GRF 1-29, Macimorelin or Pasireotide in people; PubMed searches for each find no human dosing data (for tirzepatide only case reports, and the GHRP-2 data come from infusions given together with TRH). The melanocortin peptides, BPC-157, TB-500 and the rest of our library have no human free T3 data either.

PeptideMeasuredEffect on Free T3Size of effectEvidence
IGF-1 (Insulin-Like Growth Factor 1)Free T3RaisesNo figure in the abstract: eight healthy adults given recombinant IGF-1 by subcutaneous infusion (10 micrograms/kg per hour) for 5 days had higher free T3 and lower TSH, with free T4 unchanged; adults with pituitary disease on levothyroxine also had higher free T3 after 7 days. In Laron-type dwarfism, months of IGF-1 did not change total T3Raised free T3 in one small study; total T3 did not change in another. [19] [20]Human trials
LeptinLow-leptin states (lipodystrophy, hypothalamic amenorrhea)Free T3Raises17 people with lipodystrophy starting metreleptin, 14 days: free T3 +19.4% (40 ± 49 pg/dL; P = 0.01); in 8 people who stopped it for 14 days, free T3 fell 8.0%. Eight women with hypothalamic amenorrhea on recombinant leptin for up to three months: free T3 rose significantlyReplacing missing leptin raises free T3. [15] [21]Human trials
MK-677 (Ibutamoren)Free T3RaisesTwenty-four healthy obese men, 25 mg/day vs placebo for 8 weeks (sustained): free T3 higher than placebo at 8 weeks (P < 0.05), not at 2 weeks; no figure in the abstract. 18 children with GH deficiency, 0.8 mg/kg per day for 8 days: total T3 unchangedA late rise in free T3 after 8 weeks, in line with growth hormone speeding T4-to-T3 conversion. [13] [22]Human trials
Thyrotropin-Releasing Hormone (TRH)Free T3Raises10 elderly euthyroid hospital patients with cerebrovascular disease, TRH tartrate 2 mg/day for 3 weeks (sustained): free T3 rose 12.5% on average (total T3 8.3%), within normal values; 9 untreated controls did not change. 20 euthyroid patients, 4 mg TRH tartrate IM daily for 30 days: free T3, T4 and free T4 rose while TSH fellRepeated TRH dosing nudges free T3 up modestly, staying inside the normal range. [14] [23]Human trials
Adrenocorticotropic Hormone (ACTH)Total T3Lowers38 hospitalized patients with acute gout and normal thyroid function (32 analysed), single 1 mg IM dose of synthetic ACTH (acute): total T3 lower at 24 h but not at 48 h (free T3 not measured)A brief dip in total T3 after one large dose. [18]Human trials
CosyntropinFree T3LowersNo figure in the abstract: in 26 children with West syndrome given daily low-dose tetracosactide-zinc (0.01 mg/kg/day) with pyridoxal phosphate, ACTH therapy transiently suppressed free T3, T3, T4 and free T4A temporary fall during daily treatment in children. [24]Human trials
LanreotideTSH-secreting pituitary tumorsFree T3LowersEighteen patients with TSH-secreting pituitary tumors, slow-release lanreotide 30 mg every 10 to 14 days for 6 months: free T3 14.6 to 8.3 pmol/L (P < 0.01). 13 patients on lanreotide autogel 90 mg every 4 weeks: free T3 fell and euthyroid status was maintainedLowers free T3 toward normal in TSH-secreting pituitary tumors. [16] [25]Human trials
OctreotideTSH-secreting pituitary tumorsFree T3LowersFive patients with TSH-secreting tumors, 100 micrograms three times daily for 5 days: TSH fell 86% on average and free T3 and free T4 normalized. Six women and 5 men with TSH-secreting adenomas on monthly octreotide LAR 20 mg: free T4/T3 fell after 3 monthsBrings high free T3 back to normal in TSH-secreting pituitary tumors, its main thyroid use. [26] [27]Human trials
SomatostatinOveractive thyroidFree T3Lowers7 hyperthyroid patients, the same 12-h infusion (acute): free T3 and T3 fell significantly while reverse T3 rose; T4 and free T4 unchangedLowers free T3 in an overactive thyroid by slowing T4-to-T3 conversion. [17]Human trials
CalcitoninTotal T3No clear effect14 healthy volunteers, single 50 MRCU dose of salmon calcitonin (acute): total T3 did not change significantly within 120 min (free T3 not measured)Single-dose data only; total T3 unchanged. [28]Human trials
ExenatideFree T3No clear effectType 2 diabetes without thyroid disease, 6 months (46 enrolled, 13 excluded): free T3 unchanged while TSH fell from 2.3 to 1.8 mIU/L. 39 obese adults with type 2 diabetes, 5 then 10 micrograms twice daily for 6 months: free T3 did not changeFree T3 did not change over 6 months in two before-after studies. [29] [30]Human trials
GhrelinFree T3No clear effect20 healthy adults, ghrelin 50 micrograms at 2200, 2300, 0000 and 0100 h (crossover vs placebo, acute): free T3 not affected, while free T4 rose slightly and TSH fellOvernight ghrelin left free T3 unchanged. [31]Human trials
HexarelinTotal T3No clear effectAll 12 subjects (ten children with familial short stature, two adults with GH deficiency), hexarelin 1 microgram/kg IV or 20 micrograms/kg intranasal (acute, sampled to 120 minutes): no significant change in total T3 or free T4 (free T3 not measured); TSH fellSingle doses only; total T3 unchanged. [32]Human trials
LeptinOverweight or obesity on a dietFree T3No clear effect24 overweight and obese adults on a hypocaloric diet, metreleptin 10 mg/day (n=18) or placebo (n=6) for 6 months: free T3 fell with weight loss in both groups, with no difference between themExtra leptin on top of normal levels does not stop the diet-related fall in free T3. [7]Human trials
LeuprolideFree T3No clear effectMeta-analysis of 22 studies in children with central precocious puberty on GnRH agonists (leuprolide and related drugs): no significant change in free T3, free T4 or TSH after treatmentGnRH-agonist treatment in children did not shift free T3. [33]Human trials
LiraglutideFree T3No clear effect49 overweight or obese adults with type 2 diabetes and fatty liver, liraglutide for an average of 16 months (before-after, no placebo group): free T3 4.76 before vs 4.51 pmol/L after (p = 0.826), while TSH fellNo significant change in free T3 in one before-after study. [34]Human trials
OxytocinFree T3No clear effectSixty-one adults with obesity, intranasal oxytocin 24 IU four times daily vs placebo, 6 weeks (sustained): TSH, free T4 and free T3 did not change (P ≥ .154); the free T3/free T4 ratio rose (P = .048)Free T3 itself did not change; only the free T3 to free T4 ratio moved. [35]Human trials
SermorelinFree T3No clear effectFive healthy men, single IV dose of GHRH(1-29)-NH2 (sermorelin) 0.015 to 0.5 micrograms/kg (acute): free T3 and free T4 unchangedA single dose does not move free T3. [36]Human trials
SomatostatinNormal thyroidFree T3No clear effect17 euthyroid volunteers, somatostatin 250 micrograms IV then 500 micrograms/h for 12 h (acute): free T3, T3, T4 and free T4 unchangedA 12-hour infusion leaves free T3 unchanged in people with normal thyroid function. [17]Human trials
OctreotideAcromegaly (normal thyroid)Free T3Unclear68 people with acromegaly, 100 micrograms three times daily for 1 year: free T3 not modified. Eight people with acromegaly, 300 micrograms/day by subcutaneous infusion for 1 month: total T3 fell from 2.05 to 1.44 nmol/L (P = 0.001)Free T3 held steady in the largest study; total T3 dipped in a smaller one. [37] [38]Human trials

What high or low results can mean

A high result

Above 4.4 pg/mL at Labcorp or 4.2 at Quest is high. With a low TSH it points to an overactive thyroid; a high free T3 with a normal free T4 is T3 toxicosis.

  • Graves disease
  • An autonomously secreting thyroid nodule
  • Too much T3 or thyroid medicine
  • Assay interference (antibodies, biotin)

Next step: Read it with TSH and free T4, and discuss the cause of an overactive thyroid with a clinician.

Sources: [1] [2] [10] [39]

A low result

Below 2.0 pg/mL at Labcorp or 2.3 at Quest is low. On its own a low free T3 is common with dieting and weight loss; in an underactive thyroid it falls late, after TSH and free T4.

  • Weight loss or calorie restriction
  • Late hypothyroidism
  • Somatostatin analogs or glucocorticoids

Next step: Check TSH and free T4 before acting on a low free T3.

Sources: [1] [2] [7]

How the test works

SampleSerum (preferred) or plasma, 1 mL at Labcorp, in a red-top, gel-barrier or lithium-heparin tube; not oxalate, EDTA or citrate.
FastingLabcorp lists no fasting requirement.
TimingUsually ordered after a low TSH, especially when free T4 is not raised. Stop high-dose biotin at least 72 hours before the draw.
Lab differencesLabcorp uses an ECLIA on the Roche cobas and Quest an immunoassay; Quest also offers tracer dialysis (36598). Antibodies to thyroid hormones can interfere with free hormone immunoassays.
RetestingCompare results from the same lab and method, and note any recent weight loss or illness.
Labcorp order code010389: Triiodothyronine (T3), Free
Quest Diagnostics order code34429: T3, Free
LOINC codes
  • 3051-0: Triiodothyronine (T3) Free [Mass/volume] in Serum or Plasma
  • 29239-1: Triiodothyronine (T3) Free [Mass/volume] in Serum or Plasma by Dialysis (tracer dialysis, the code Quest 36598 reports)
  • 14928-6: Triiodothyronine (T3) Free [Moles/volume] in Serum or Plasma (the same test in pmol/L, used outside the US)
LOINC 3051-0 on loinc.org

Sources: [1] [2] [9]

History

T3 was discovered decades after T4, and it took until 1970 to show that most of it is made from T4 outside the thyroid.

  1. 1952Gross and Pitt-Rivers report the physiological activity of 3:5:3'-L-triiodothyronine (T3). [40]
  2. 1970Braverman and colleagues show that people without a thyroid convert T4 to T3. [3]
  3. 1971Sterling and colleagues publish on free thyroxine and free triiodothyronine together. [41]
  4. 2014The American Thyroid Association keeps levothyroxine alone as standard treatment, finding no consistently strong evidence for adding T3. [11]

FAQ

What is a normal free T3?

For adults, Labcorp prints 2.0-4.4 pg/mL and Quest 2.3-4.2 pg/mL. Children have their own, higher ranges.

Sources: [1] [2]

When is free T3 ordered?

Usually after a low TSH or when hyperthyroidism is suspected, especially if free T4 is not raised.

Sources: [2]

What is T3 toxicosis?

An overactive thyroid that shows only in T3: up to 10% of people with proven hyperthyroidism have a high free T3 with a normal free T4.

Sources: [2]

Is free T3 useful for an underactive thyroid?

Not much. Free T3 may not drop until well after TSH and free T4 have changed, so TSH and free T4 are the tests to use.

Sources: [2]

What is the difference between free T3 and total T3?

Total T3 includes the T3 bound to carrier proteins. Only about 0.25% of T3 is free, and free T3 is unaffected by changes in those proteins.

Sources: [1]

Does weight loss lower free T3?

Yes. Free T3 fell with diet-induced weight loss in a six-month trial, whether or not people took leptin, and fell markedly in people with diabetes after weight-loss treatment (bariatric surgery, a GLP-1 drug or lifestyle change, analysed together).

Sources: [7] [8]

Do growth hormone peptides raise free T3?

Growth hormone speeds T4-to-T3 conversion: in adults with growth hormone deficiency, median free T3 rose from 2.38 to 2.78 pg/mL on treatment. MK-677 (Ibutamoren) raised free T3 after 8 weeks; single doses of Sermorelin did not change it.

Sources: [5] [13] [36]

Do GLP-1 drugs change free T3?

In the studies that measured it, no: free T3 did not change over 6 months on Exenatide or about 16 months on Liraglutide. No trial has reported free T3 on Semaglutide or Tirzepatide.

Sources: [29] [34] [42]

Do GLP-1 drugs like semaglutide or tirzepatide cause thyroid cancer?

Their labels carry a boxed warning: Semaglutide, Tirzepatide, Liraglutide and Dulaglutide caused thyroid C-cell tumors in rodents, and it is unknown whether they do in humans. They must not be used with a personal or family history of medullary thyroid carcinoma (MTC) or MEN 2. MTC starts in the C-cells, which make calcitonin rather than thyroid hormone, so a thyroid hormone test does not screen for it; the labels add that routine calcitonin or ultrasound monitoring is of uncertain value.

Sources: [43] [44] [45] [46] [47] [48]

Do I need to stop biotin before a free T3 test?

Yes, if you take high-dose biotin: Labcorp asks you to stop at least 72 hours before the sample.

Sources: [1]

Is there a pregnancy range for free T3?

Only on Quest's dialysis test, which prints 200-380 pg/dL for all trimesters.

Sources: [9]

Why do some labs report free T3 in pmol/L?

pmol/L is the SI unit used outside the US. Divide pmol/L by 1.536 to get pg/mL.

Sources: [10]

References

  1. Labcorp. Test 010389: Triiodothyronine (T3), Free. Use, special instructions, limitations, specimen requirements, reference range by age and LOINC map. labcorp.com/tests/010389/triiodothyronine-t3-free
  2. Quest Diagnostics. Test code 34429: T3, Free. Test directory: methodology, clinical significance, reference ranges by age and LOINC. testdirectory.questdiagnostics.com/test/test-detail/34429/t3-free?cc=PHP
  3. Braverman LE, Ingbar SH, Sterling K. Conversion of thyroxine (T4) to triiodothyronine (T3) in athyreotic human subjects. J Clin Invest. 1970;49(5):855-64. PMID 4986007
  4. Quest Diagnostics. Test code 7444: Thyroid Panel with TSH. Test directory: components, clinical significance and LOINC. testdirectory.questdiagnostics.com/test/test-detail/7444/thyroid-panel-with-tsh?cc=PHP
  5. Yamauchi I, Sakane Y, Yamashita T, et al. Effects of growth hormone on thyroid function are mediated by type 2 iodothyronine deiodinase in humans. Endocrine. 2018;59(2):353-363. PMID 29274063
  6. Jørgensen JO, Møller J, Laursen T, et al. Growth hormone administration stimulates energy expenditure and extrathyroidal conversion of thyroxine to triiodothyronine in a dose-dependent manner and suppresses circadian thyrotrophin levels: studies in GH-deficient adults. Clin Endocrinol (Oxf). 1994;41(5):609-14. PMID 7828350
  7. Shetty GK, Matarese G, Magkos F, et al. Leptin administration to overweight and obese subjects for 6 months increases free leptin concentrations but does not alter circulating hormones of the thyroid and IGF axes during weight loss induced by a mild hypocaloric diet. Eur J Endocrinol. 2011;165(2):249-54. PMID 21602313
  8. Li P, Zhang J, Li M. Associations between thyroid axis changes and glycemic improvement after weight loss in type 2 diabetes: a mediation analysis. Am J Transl Res. 2026;18(7):6284-6305. PMID 42631139
  9. Quest Diagnostics. Test code 36598: T3, Free, Tracer Dialysis. Test directory: methodology, reference ranges (including pregnancy) and LOINC. testdirectory.questdiagnostics.com/test/test-detail/36598/t3-free-tracer-dialysis?cc=PHP
  10. Moran C, Schoenmakers N, Halsall D, et al. Approach to the Patient With Raised Thyroid Hormones and Nonsuppressed TSH. J Clin Endocrinol Metab. 2024;109(4):1094-1108. PMID 37988295
  11. Jonklaas J, Bianco AC, Bauer AJ, et al. Guidelines for the treatment of hypothyroidism: prepared by the american thyroid association task force on thyroid hormone replacement. Thyroid. 2014;24(12):1670-751. PMID 25266247
  12. Kiren G, Yılmaz Çalık G, Güngören M, et al. Age- and Sex-Specific Reference Intervals for TSH, FT4, and FT3 Derived from the Turkish Multi-Center Cohort. Diagnostics (Basel). 2026;16(12). PMID 42351459
  13. Svensson J, Carlsson B, Carlsson LM, et al. Discrepancy between serum leptin values and total body fat in response to the oral growth hormone secretagogue MK-677. Clin Endocrinol (Oxf). 1999;50(4):451-6. PMID 10468903
  14. Custro N, Scafidi V, Costanzo G, et al. [Changes in blood levels of the pituitary-thyroid axis observed during therapy with protirelin ++ in hospitalized euthyroid patients with cerebrovascular disease]. Minerva Med. 1991;82(7-8):453-7. PMID 1922889
  15. Grover A, Quaye E, Brychta RJ, et al. Leptin Decreases Energy Expenditure Despite Increased Thyroid Hormone in Patients With Lipodystrophy. J Clin Endocrinol Metab. 2021;106(10):e4163-e4178. PMID 33890058
  16. Kuhn JM, Arlot S, Lefebvre H, et al. Evaluation of the treatment of thyrotropin-secreting pituitary adenomas with a slow release formulation of the somatostatin analog lanreotide. J Clin Endocrinol Metab. 2000;85(4):1487-91. PMID 10770186
  17. De Rosa G, Corsello SM, Della Casa S, et al. Effect of somatostatin on the pituitary-thyroid axis. Ann Endocrinol (Paris). 1983;44(6):355-60. PMID 6146290
  18. Markantes GK, Daoussis D, Mamali I, et al. Differences in thyroid function tests after administration of a single supraphysiological dose of ACTH or a high dose of a synthetic steroid. Steroids. 2022;182:109009. PMID 35283116
  19. Hussain MA, Schmitz O, Jorgensen JO, et al. Insulin-like growth factor I alters peripheral thyroid hormone metabolism in humans: comparison with growth hormone. Eur J Endocrinol. 1996;134(5):563-7. PMID 8664976
  20. Klinger B, Ionesco A, Anin S, et al. Effect of insulin-like growth factor I on the thyroid axis in patients with Laron-type dwarfism and healthy subjects. Acta Endocrinol (Copenh). 1992;127(6):515-9. PMID 1362849
  21. Welt CK, Chan JL, Bullen J, et al. Recombinant human leptin in women with hypothalamic amenorrhea. N Engl J Med. 2004;351(10):987-97. PMID 15342807
  22. Codner E, Cassorla F, Tiulpakov AN, et al. Effects of oral administration of ibutamoren mesylate, a nonpeptide growth hormone secretagogue, on the growth hormone-insulin-like growth factor I axis in growth hormone-deficient children. Clin Pharmacol Ther. 2001;70(1):91-8. PMID 11452249
  23. Monzani F, Pucci E, Fierabracci P, et al. Long-term intramuscular administration of thyrotropin-releasing hormone tartrate in patients with cerebrovascular disease: effects on the pituitary-thyroid axis. Horm Res. 1991;35(3-4):146-50. PMID 1806468
  24. Seki T. Combination treatment of high-dose pyridoxal phosphate and low-dose ACTH in children with West syndrome and related disorders. Jpn J Psychiatry Neurol. 1990;44(2):219-37. PMID 1701836
  25. Shimatsu A, Nakamura A, Takahashi Y, et al. Preoperative and long-term efficacy and safety of lanreotide autogel in patients with thyrotropin-secreting pituitary adenoma: a multicenter, single-arm, phase 3 study in Japan. Endocr J. 2021;68(7):791-805. PMID 33692246
  26. Beck-Peccoz P, Mariotti S, Guillausseau PJ, et al. Treatment of hyperthyroidism due to inappropriate secretion of thyrotropin with the somatostatin analog SMS 201-995. J Clin Endocrinol Metab. 1989;68(1):208-14. PMID 2491862
  27. Caron P, Arlot S, Bauters C, et al. Efficacy of the long-acting octreotide formulation (octreotide-LAR) in patients with thyrotropin-secreting pituitary adenomas. J Clin Endocrinol Metab. 2001;86(6):2849-53. PMID 11397898
  28. Zofková I, Bednár J. Calcitonin inhibits TRH-induced TSH secretion. Exp Clin Endocrinol. 1984;83(3):263-8. PMID 6432564
  29. Sencar ME, Sakiz D, Calapkulu M, et al. The Effect of Exenatide on Thyroid-Stimulating Hormone and Thyroid Volume. Eur Thyroid J. 2019;8(6):307-311. PMID 31934556
  30. Köseoğlu D, Özdemir Başer Ö, Berker D, et al. EXENATIDE TREATMENT REDUCES THYROID GLAND VOLUME, BUT HAS NO EFFECT ON THE SIZE OF THYROID NODULES. Acta Endocrinol (Buchar). 2020;16(3):275-279. PMID 33363646
  31. Kluge M, Riedl S, Uhr M, et al. Ghrelin affects the hypothalamus-pituitary-thyroid axis in humans by increasing free thyroxine and decreasing TSH in plasma. Eur J Endocrinol. 2010;162(6):1059-65. PMID 20423986
  32. Laron Z, Frenkel J, Gil-Ad I, et al. Growth hormone releasing activity by intranasal administration of a synthetic hexapeptide (hexarelin). Clin Endocrinol (Oxf). 1994;41(4):539-41. PMID 7955465
  33. Guo N, Zhou F, Jiang X, et al. The effect of gonadotropin-releasing hormone analog treatment on the endocrine system in central precocious puberty patients: a meta-analysis. J Pediatr Endocrinol Metab. 2024;37(3):197-208. PMID 38235550
  34. Ye J, Xu J, Wen W, et al. Effect of Liraglutide on Serum TSH Levels in Patients with NAFLD and its Underlying Mechanisms. Int J Clin Pract. 2022;2022:1786559. PMID 36311486
  35. Galbiati F, Wronski ML, Bitar T, et al. Oxytocin-induced changes in free T3/free T4 ratio and relationship with quality of life in adults with obesity. J Clin Endocrinol Metab. 2026. PMID 42714565
  36. Barron JL, Coy DH, Millar RP. Growth hormone responses to growth hormone-releasing hormone (1-29)-NH2 and a D-Ala2 analog in normal men. Peptides. 1985;6(3):575-7. PMID 2866496
  37. Arosio M, Macchelli S, Rossi CM, et al. Effects of treatment with octreotide in acromegalic patients--a multicenter Italian study. Italian Multicenter Octreotide Study Group. Eur J Endocrinol. 1995;133(4):430-9. PMID 7581966
  38. Roelfsema F, Frölich M. Pulsatile thyrotropin release and thyroid function in acromegalics before and during subcutaneous octreotide infusion. J Clin Endocrinol Metab. 1991;72(1):77-82. PMID 1986030
  39. Ross DS, Burch HB, Cooper DS, et al. 2016 American Thyroid Association Guidelines for Diagnosis and Management of Hyperthyroidism and Other Causes of Thyrotoxicosis. Thyroid. 2016;26(10):1343-1421. PMID 27521067
  40. GROSS J, PITT-RIVERS R. Physiological activity of 3:5:3'-L-triiodothyronine. Lancet. 1952;1(6708):593-4. PMID 14909477
  41. Sterling K. Free thyroxine and triiodothyronine. CRC Crit Rev Clin Lab Sci. 1971;2(2):223-42. PMID 4950949
  42. Salama S, Elfaki Omer EO, Mahmoud A, et al. Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists and Thyroid Function Tests: A Systematic Review Identifying a Critical Evidence Gap. Cureus. 2026;18(4):e108005. PMID 42220875
  43. Wegovy (semaglutide) injection 2.4 mg. FDA prescribing information, Table 10 (cardiometabolic parameters, Study 2). dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b
  44. MOUNJARO (tirzepatide) injection, prescribing information. DailyMed. dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d2d7da5d-ad07-4228-955f-cf7e355c8cc0
  45. Zepbound (tirzepatide) injection. FDA prescribing information, Table 3 (cardiometabolic parameters, Studies 1 and 2). dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b
  46. VICTOZA (liraglutide) injection, prescribing information. DailyMed. dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5a9ef4ea-c76a-4d34-a604-27c5b505f5a4
  47. TRULICITY (dulaglutide) injection, prescribing information. DailyMed. dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=463050bd-2b1c-40f5-b3c3-0a04bb433309
  48. Wells SA, Asa SL, Dralle H, et al. Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma. Thyroid. 2015;25(6):567-610. PMID 25810047

Educational information, not medical advice. Lab ranges and test codes were checked on November 3, 2026. Always use the range printed on your own report, and talk to a clinician about your results.